Downer Cow Syndrome

Downer cow syndrome (DCS) is a clinical condition in cattle characterized by the inability to stand or remain standing for more than 24 hours, despite normal mentation and absence of obvious fractures or nerve paralysis. It is a complex, multifactorial syndrome that occurs most commonly in periparturient dairy cows, particularly high-producing Holstein-Friesians, but can also affect beef cattle. The syndrome encompasses a spectrum of metabolic, traumatic, and toxic etiologies, often culminating in recumbency, muscle and nerve damage, and secondary complications such as decubital ulcers, aspiration pneumonia, and sepsis. DCS is a major economic burden due to treatment costs, milk loss, increased culling, and mortality. It is distinct from 'downer' cows that are alert but unable to rise, and from those with specific neurological deficits. The syndrome is a clinical entity that requires rapid, systematic diagnosis and aggressive therapy to optimize recovery.

The etiology of downer cow syndrome is multifactorial, with primary causes including metabolic disorders such as clinical hypocalcemia (milk fever), hypomagnesemia, hypophosphatemia, and hyperkalemia. Traumatic injuries, including pelvic fractures, femoral fractures, and muscle damage from calving paralysis, are common. Toxemias from mastitis, metritis, or peritonitis can lead to systemic inflammatory response syndrome (SIRS) and recumbency. Nutritional deficiencies, particularly of calcium, phosphorus, magnesium, and vitamin E/selenium, predispose to muscle weakness. Additionally, prolonged recumbency from any cause leads to pressure-induced ischemia of the large muscle groups of the hindlimbs, resulting in ischemic myopathy and neuropathy, which perpetuates the downer state. In some cases, the exact cause remains undetermined, and the syndrome is classified as 'idiopathic downer cow syndrome.'

Downer cow syndrome predominantly affects dairy cows in the periparturient period, with the highest incidence in the first 24 to 72 hours after calving. High-producing Holstein-Friesian cows are overrepresented, likely due to the high metabolic demands of lactation. Beef cattle are less commonly affected but can develop DCS following calving or transport. The incidence in dairy herds ranges from 1% to 5% of calvings, with a case fatality rate of 20% to 40%. Older cows (≥3rd lactation) are at higher risk due to increased milk production and greater susceptibility to hypocalcemia. Herd-level risk factors include poor transition cow management, inadequate dietary cation-anion difference (DCAD) in dry cow rations, and high stocking density. Seasonally, calving in winter months may increase risk due to slippery surfaces and reduced vitamin D synthesis. Economic losses include treatment costs, milk loss, increased culling, and mortality, estimated at $300 to $500 per affected cow.

The pathophysiology of downer cow syndrome involves a cascade of metabolic and ischemic events. Primary metabolic disturbances, such as hypocalcemia, impair neuromuscular function, leading to muscle weakness and recumbency. Hypocalcemia reduces the release of acetylcholine at the neuromuscular junction, decreasing muscle contractility. Hypomagnesemia exacerbates this by interfering with parathyroid hormone action and causing neuronal hyperexcitability. Hypophosphatemia contributes to muscle weakness and may impair energy metabolism. When a cow becomes recumbent, prolonged pressure on the large hindlimb muscles (e.g., semimembranosus, semitendinosus, quadriceps) causes ischemia and reperfusion injury, leading to muscle necrosis and release of myoglobin and creatine kinase. This ischemic myopathy further weakens the muscles, making standing impossible. Additionally, compression of the sciatic and obturator nerves can cause neuropraxia or axonotmesis, resulting in hindlimb paralysis. Secondary complications, such as decubital ulcers, aspiration pneumonia, and sepsis, arise from prolonged recumbency and immunosuppression, further worsening the prognosis.

Intrinsic predisposing factors include high milk yield, increasing parity (≥3), genetics (Holstein breed), and the physiological stress of the transition period. Cows with a history of milk fever or dystocia are at higher risk. Extrinsic factors include nutritional mismanagement, such as low dietary calcium or high potassium in dry cow rations, leading to hypocalcemia. Inadequate energy and protein intake prepartum can cause fatty liver and immunosuppression. Environmental factors include slippery flooring, overcrowding, and poor footing in calving areas. Poor hygiene and dirty bedding increase the risk of mastitis and metritis, which can lead to toxemia and recumbency. Additionally, rough handling during calving or transport can cause traumatic injuries. Management practices that delay treatment of milk fever or other metabolic disorders increase the likelihood of progression to DCS.

Clinical signs of downer cow syndrome include an alert, bright cow that is unable to rise or remains sternally recumbent. The cow may attempt to stand but fails, often with hindlimbs splayed. Appetite may be reduced, and there may be signs of dehydration. Body temperature is usually normal unless secondary infection is present. Heart rate and respiratory rate may be elevated due to stress or pain. Rumen motility is often decreased or absent. The cow may exhibit signs of hypocalcemia, such as muscle tremors, cold extremities, and bloat. If the cause is traumatic, there may be swelling, crepitus, or abnormal limb positioning. Neurological deficits, such as knuckling of the fetlocks or loss of conscious proprioception, may be present. In cases of toxemia, there may be fever, injected mucous membranes, and signs of systemic inflammatory response syndrome (SIRS), such as tachycardia and tachypnea. Decubital ulcers may develop over bony prominences within 24 to 48 hours of recumbency.

Differential diagnoses for downer cow syndrome include: 1) Milk fever (clinical hypocalcemia) – typically occurs within 72 hours post-calving, responds to calcium therapy, and may progress to DCS if untreated. 2) Calving paralysis (obturator or sciatic nerve injury) – often associated with dystocia, with specific neurological deficits. 3) Pelvic or femoral fractures – history of trauma, crepitus, and inability to bear weight. 4) Severe mastitis (coliform mastitis) – signs of toxemia, udder swelling, and abnormal milk. 5) Metritis – foul-smelling vaginal discharge, fever, and uterine enlargement. 6) Peritonitis – abdominal pain, fever, and decreased rumen motility. 7) Spinal cord injury or vertebral fracture – neurological deficits, ataxia, and possible paralysis. 8) Botulism – progressive flaccid paralysis, often in outbreaks. 9) Hypomagnesemia (grass tetany) – hyperesthesia, muscle tremors, and convulsions, often in lactating cows on pasture. 10) Fatty liver disease (hepatic lipidosis) – ketosis, depression, and poor response to treatment. Differentiation relies on thorough physical examination, neurological assessment, laboratory tests, and response to therapy.

The diagnostic approach to downer cow syndrome should be systematic and rapid. Step 1: Perform a complete physical examination, including temperature, heart rate, respiratory rate, rumen motility, and assessment of hydration status. Step 2: Evaluate the cow's ability to stand and assess for neurological deficits, fractures, or muscle damage. Step 3: Perform a rectal examination to assess for uterine or abdominal abnormalities. Step 4: Collect blood samples for biochemistry (calcium, magnesium, phosphorus, potassium, BHB, NEFA, CK, AST) and complete blood count. Step 5: Perform a urinalysis for ketones and myoglobin. Step 6: If mastitis is suspected, perform a California Mastitis Test (CMT) and collect milk for culture. Step 7: If traumatic injury is suspected, perform radiography or ultrasonography of the pelvis and hindlimbs. Step 8: If metabolic disease is suspected, administer a therapeutic trial of calcium and monitor response. Step 9: If the cow does not respond to initial therapy within 24 hours, reassess and consider additional diagnostics such as abdominal ultrasonography to rule out peritonitis or abomasal displacement. Step 10: In cases of prolonged recumbency, assess for secondary complications such as decubital ulcers and muscle necrosis.

Laboratory findings in downer cow syndrome vary depending on the underlying cause. In hypocalcemia, blood ionized calcium is <1.0 mmol/L (reference range: 1.1-1.3 mmol/L). Hypomagnesemia is defined as serum magnesium <0.75 mmol/L. Hypophosphatemia is serum phosphorus <1.2 mmol/L. Hyperkalemia may be present in cases of muscle necrosis or acidosis. Blood BHB levels >1.2 mmol/L indicate subclinical ketosis, and >3.0 mmol/L indicate clinical ketosis. NEFA levels >0.5 mmol/L in fresh cows indicate negative energy balance. Creatine kinase (CK) and aspartate aminotransferase (AST) are elevated in muscle damage, with CK often >10,000 U/L. Complete blood count may show leukopenia or leukocytosis with a left shift in cases of sepsis. Fibrinogen levels may be elevated (>5 g/L) in inflammatory conditions. Rumen fluid analysis may show pH <5.5 in ruminal acidosis, decreased protozoal motility, and prolonged methylene blue reduction time (>3 minutes). Milk SCC >200,000 cells/mL indicates subclinical mastitis, and >1,000,000 cells/mL suggests clinical mastitis.

Imaging modalities are useful in diagnosing underlying causes of downer cow syndrome. Ultrasonography of the abdomen can assess rumen motility, reticular contractions, and the presence of free fluid or abscesses. It can also evaluate the liver for lipidosis (increased echogenicity) and the kidneys for hydronephrosis. Ultrasonography of the hindlimbs can detect muscle damage, hematomas, or fractures. Radiography is valuable for diagnosing pelvic fractures, vertebral fractures, or foreign bodies in the reticulum (hardware disease). In cases of suspected mastitis, ultrasonography of the udder can reveal abscesses or fibrosis. Thoracic ultrasonography may detect pneumonia or pleural effusion in cases of aspiration. Advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) is rarely used in field settings but can provide detailed information on spinal cord or muscle pathology.

Cytological and histopathological findings are important for confirming the underlying cause and assessing secondary damage. Peritoneal fluid cytology may show increased neutrophils and protein in peritonitis. Milk cytology from mastitic quarters shows high somatic cell counts with neutrophils and bacteria. Muscle biopsy from affected hindlimb muscles reveals myofiber degeneration, necrosis, and infiltration of macrophages and neutrophils. Liver biopsy may show lipid vacuolation in fatty liver disease. Histopathology of the sciatic nerve may show Wallerian degeneration in cases of nerve compression. In cases of sepsis, histopathology of multiple organs may show microabscesses and inflammatory infiltrates. Necropsy findings in fatal cases include decubital ulcers, muscle necrosis, and evidence of the primary disease process.

Treatment of downer cow syndrome must be aggressive and multifaceted. Immediate stabilization includes providing a soft, non-slippery surface with adequate bedding, and turning the cow every 2-4 hours to prevent decubital ulcers. Fluid therapy is critical: hypertonic saline (7.2% NaCl) at 4-5 mL/kg IV over 10-15 minutes, followed by oral fluids (20-30 L) via stomach tube. Calcium supplementation is essential if hypocalcemia is present: 500 mL of 23% calcium borogluconate IV slowly, or 1-2 bottles of oral calcium gel. Magnesium sulfate (50-100 g) can be given subcutaneously or orally if hypomagnesemia is suspected. Phosphorus supplementation (sodium phosphate) may be needed. Anti-inflammatory therapy with flunixin meglumine (1.1-2.2 mg/kg IV) or meloxicam (0.5 mg/kg SC) reduces pain and inflammation. Antibiotics are indicated if infection is present: ceftiofur (2.2 mg/kg SC q24h) or oxytetracycline (10 mg/kg IV/IM q24h). In cases of toxemia, supportive care with electrolytes and glucose is important. Surgical intervention may be necessary for fractures or abscess drainage. Nutritional support with propylene glycol (250-500 mL orally q12h) is used for ketosis. The cow should be assisted to stand using a hip lift or sling, but only if she is able to bear weight. Prognosis is guarded if the cow does not improve within 48-72 hours.

The prognosis for downer cow syndrome depends on the underlying cause, duration of recumbency, and response to treatment. Cows with milk fever that respond to calcium therapy within 24 hours have a good prognosis (80-90% recovery). However, if recumbency persists beyond 24 hours, the prognosis worsens significantly, with recovery rates dropping to 50% or less. Cows with traumatic fractures or severe muscle damage have a poor prognosis. Negative prognostic indicators include: recumbency >48 hours, development of decubital ulcers, elevated CK >20,000 U/L, and lack of improvement after 72 hours of treatment. Cows that do recover may have reduced milk yield in the current lactation and are at higher risk for culling. Reproductive performance may be impaired due to prolonged recumbency and stress. Long-term survival is lower compared to unaffected herdmates.

Follow-up care for downer cow syndrome involves daily monitoring of the cow's ability to stand, appetite, fecal output, and urine production. Blood biochemistry should be rechecked every 24-48 hours to monitor calcium, magnesium, phosphorus, and BHB levels. Rumen fluid pH should be assessed if ruminal acidosis is suspected. Milk yield should be recorded daily, and SCC monitored if mastitis was present. The cow should be turned every 2-4 hours to prevent pressure sores. Nutritional support should be continued until the cow is eating and drinking normally. Herd-level follow-up includes reviewing transition cow management, DCAD of dry cow rations, and calving area hygiene. A transition cow audit should be performed to identify risk factors for metabolic disease. Ration formulation should be reviewed by a nutritionist to ensure adequate calcium, phosphorus, magnesium, and energy. Vaccination and mastitis control programs should be evaluated.

Clinical pearls: 1) Always rule out hypocalcemia first in any downer cow, as it is the most common cause and easily treatable. 2) Use a hip lift to assist standing only if the cow can bear weight; otherwise, it may cause further muscle damage. 3) Provide excellent footing and padding to prevent secondary injuries. 4) Monitor for secondary complications such as mastitis, pneumonia, and decubital ulcers. 5) Early aggressive therapy improves prognosis. Pitfalls: 1) Delaying treatment for hypocalcemia can lead to irreversible muscle damage. 2) Overlooking traumatic injuries can lead to inappropriate treatment. 3) Using excessive force when attempting to stand a cow can cause fractures. 4) Neglecting to turn the cow leads to pressure necrosis. 5) Failing to address underlying toxemia can result in death. 6) Administering calcium too rapidly can cause cardiac arrhythmias. 7) Not considering hypomagnesemia in cows that do not respond to calcium therapy.

Current drug protocols for downer cow syndrome include: 1) Calcium: 23% calcium borogluconate, 500 mL IV over 10-15 minutes, or 1-2 bottles (400-500 mL) oral calcium gel. Withdrawal: zero for milk and meat if used as directed. 2) Magnesium: 50-100 g magnesium sulfate SC or IV as a 20% solution, or oral magnesium oxide. 3) Phosphorus: 30-60 g sodium phosphate IV or oral. 4) Flunixin meglumine: 1.1-2.2 mg/kg IV, q24h for up to 3 days. Withdrawal: milk 36 hours, meat 4 days. 5) Meloxicam: 0.5 mg/kg SC, single dose. Withdrawal: milk 5 days, meat 15 days. 6) Ceftiofur: 2.2 mg/kg SC q24h for 3-5 days. Withdrawal: milk 0 hours, meat 3 days. 7) Oxytetracycline: 10 mg/kg IV or IM q24h. Withdrawal: milk 96 hours, meat 28 days. 8) Propylene glycol: 250-500 mL orally q12h for 3-5 days. 9) Hypertonic saline: 7.2% NaCl, 4-5 mL/kg IV over 10-15 minutes. 10) Oral fluids: 20-30 L of electrolyte solution via stomach tube. 11) Antibiotics for mastitis: intramammary infusions such as ceftiofur hydrochloride (125 mg per quarter) or amoxicillin trihydrate (200 mg per quarter) q12h for 2-3 days. Withdrawal times vary by product. Always consult the label and veterinarian for specific withdrawal times.

Evidence-based literature on downer cow syndrome includes landmark studies on the efficacy of calcium therapy in milk fever, such as the classic work by Jorgensen (1974) demonstrating that IV calcium borogluconate is effective in 80% of cases. Research by Goff and Horst (1997) highlighted the importance of DCAD in preventing hypocalcemia. Studies on the use of hypertonic saline in recumbent cows (Constable et al., 1998) showed improved cardiovascular function and survival. A meta-analysis by LeBlanc et al. (2005) on transition cow management emphasized the role of nutrition in preventing metabolic diseases. Consensus guidelines from the American Association of Bovine Practitioners (AABP) recommend a systematic approach to downer cow management, including early intervention and supportive care. Recent studies (e.g., Van Saun, 2016) have focused on the prognostic indicators of DCS, such as CK levels and duration of recumbency. Overall, the literature supports aggressive therapy and careful monitoring to improve outcomes.